Lazard Research & Insights
January 05, 2026
Annual Review of Shareholder Activism 2025
Lazard’s 2025 Review of Shareholder Activism highlights key trends and data in shareholder activism activity throughout the year.
Lazard 2025 M&A Review and 2026 Outlook
Today, Lazard published its 2025 M&A Review and 2026 Outlook Report examining the historical quantitative and qualitative drivers of M&A, the additional factors that accelerated activity in 2025, and the emerging themes that could shape dealmaking in the year ahead.
Lazard Global Biopharmaceutical Leaders Study 2025
Biopharmaceutical and biotech investors ended the summer of 2025 amid heightened uncertainty and significant financial market pressures.
